Comparison of effects of Dexmedetomidine and Midazolam in fragmented sleep related glucose changes in post operative ICU patients.
- Conditions
- Health Condition 1: O- Medical and Surgical
- Registration Number
- CTRI/2022/01/039570
- Lead Sponsor
- Calcutta national medical college hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Patient and their relatives who consented for the study
2.Adults of the age 18-55 years of age
3.Patients who got admitted in SICU, MICU following post-operative emergency surgeries.
4.Patient who received Non-invasive ventilation in form of Cpap and BiPap with better prognosis.
5.Patients who were studied within 72 hours of surgery performed.
1.Patients refused to give consent
2.Known prior diabetic history, or under Oral hypoglycemics or Insulin during or before hospital stay.
3.Paediatric patients ( <18 years)
4.Patients with allergy to study drugs
5.Liver dysfunction or confirmed renal impairment (CKD, DCLD)
6.Patients who had known neurological (Epilepsy, Guillian Barre syndrome etc) or endocrinological (cushings disease, addisons disease etc.) disorders prior to the study.
7.Patients who were diagnosed with sepsis according to the recent SIRS guidelines.
8.Pregnant patients and lactating mothers
9.Patients who were on opioids like tramadol, fentanyl infusion during the study period.
10.Known prior cardiac illness like A-V block, previous MI, pacemaker implantation.
11.Patient who are ventilated and have poor prognosis.
12.Patients who are on additional muscle relaxant infusion
13.Patients who require vasopressor like Noradrenaline or dopamine infusions to maintain Mean arterial pressure above 65 mm Hg
14.Patients admitted for severe burns or road traffic accidents
15.Patients with BMI >30 and severely obese patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Glucose levels of 180 mg/dl will be considered abnormal. Incidence of hyperglycemia (will be considered as primary outcome variable. The secondary outcome variables include severity of adverse events like nausea vomiting, degree of sedation, hemodynamic variables and average duration of hospital stay.Timepoint: 8 hourly monitoring for a period of 10 days
- Secondary Outcome Measures
Name Time Method The secondary outcome variables include severity of adverse events like nausea vomiting, degree of sedation, hemodynamic variables and average duration of hospital stay.Timepoint: Monitored continuously over a period of 10 days